Literature DB >> 3896144

Comparison of several control standard endotoxins to the National Reference Standard Endotoxin--an HIMA collaborative study.

F C Pearson, M E Weary, H E Sargent, T J Novitsky, H Lin, G Lindsay, R N Berzofsky, A L Lane, J D Wilson, J F Cooper.   

Abstract

A collaborative study, initiated under the auspices of the Health Industry Manufacturers Association (HIMA), was designed to establish the relationship of Escherichia coli O55:B5 endotoxin (the control standard endotoxin of HIMA and the Food and Drug Administration's Office of Medical Devices) to the U.S. National Reference Standard Endotoxin and to two internationally used control standard endotoxins. By using two Limulus amoebocyte lysate test systems, it was established that the E. coli O55:B5 endotoxin lot originally used by HIMA and the Office of Medical Devices to establish Limulus amoebocyte lysate release test criteria for pyrogen testing of medical devices contains approximately 4.5 endotoxin units (EU) per ng. Thus, the 1.0-ng/kg endotoxin dose limit currently established for medical devices is approximately the same as the 5.0-EU/kg endotoxin limit (on an activity basis) established by several other Food and Drug Administration agencies for human and animal parenteral drugs and biological products.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896144      PMCID: PMC238577          DOI: 10.1128/aem.50.1.91-93.1985

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  6 in total

1.  Studies in immunochemistry. 13. Preparation and properties of the 'O' somatic antigen of Shigella dysenteriae (Shiga).

Authors:  D A DAVIES; W T MORGAN; W MOSIMANN
Journal:  Biochem J       Date:  1954-04       Impact factor: 3.857

2.  Preparation and properties of a national reference endotoxin.

Authors:  J A Rudbach; F I Akiya; R J Elin; H D Hochstein; M K Luoma; E C Milner; K C Milner; K R Thomas
Journal:  J Clin Microbiol       Date:  1976-01       Impact factor: 5.948

3.  The processing and collaborative assay of a reference endotoxin.

Authors:  H D Hochstein; D F Mills; A S Outschoorn; S C Rastogi
Journal:  J Biol Stand       Date:  1983-10

4.  Pyrogenicity of E. coli 055:b5 endotoxin by the USP rabbit test--a HIMA collaborative study.

Authors:  R Dabbah; E Ferry; D A Gunther; R Hahn; P Mazur; M Neely; P Nicholas; J S Pierce; J Slade; S Watson; M Weary; R L Sanford
Journal:  J Parenter Drug Assoc       Date:  1980 May-Jun

5.  Preparation and properties of a standardized lipopolysaccharide from salmonella abortus equi (Novo-Pyrexal).

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Zentralbl Bakteriol Orig A       Date:  1979-04

6.  Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans.

Authors:  R J Elin; S M Wolff; K P McAdam; L Chedid; F Audibert; C Bernard; F Oberling
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

  6 in total
  6 in total

1.  Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice.

Authors:  H W Harris; C Grunfeld; K R Feingold; J H Rapp
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

Review 2.  Endotoxemia: methods of detection and clinical correlates.

Authors:  J C Hurley
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility.

Authors:  Dino Kocijancic; Sara Leschner; Sebastian Felgner; Ronja-Melinda Komoll; Michael Frahm; Vinay Pawar; Siegfried Weiss
Journal:  Oncotarget       Date:  2017-05-30

4.  Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Douglas B Kell
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

5.  Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

Authors:  Isaac Hurtado-Guerrero; Bruno Hernáez; María J Pinto-Medel; Esther Calonge; José L Rodriguez-Bada; Patricia Urbaneja; Ana Alonso; Natalia Mena-Vázquez; Pablo Aliaga; Shohreh Issazadeh-Navikas; José Pavia; Laura Leyva; José Alcamí; Antonio Alcamí; Óscar Fernández; Begoña Oliver-Martos
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

6.  Dodecin as carrier protein for immunizations and bioengineering applications.

Authors:  Florian Bourdeaux; Yannick Kopp; Julia Lautenschläger; Ines Gößner; Hüseyin Besir; R Martin Vabulas; Martin Grininger
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.